Floatz logo

Sinecatechins

Tobacco Use Disorder

British Columbia Cancer AgencymixturePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Tobacco Use Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
Brown University
Phase 4A
Varenicline Tartrate
University of California, San Diego
Phase 4A
Varenicline Tartrate
University of California, San Diego
Phase 4BBB
Naltrexone
Yale University
Phase 4BBB
Varenicline Tartrate
Corporal Michael J. Crescenz VA Medical Center
Phase 4BBB

View all 34 →

Same molecule, other indications

Sinecatechins is also rated in:

benign prostatic hyperplasiaDormant
CCC
Indicative ·
51 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
48 / 100
View asset →
prostate carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →